VSTM vs. EBS, RIGL, CDXS, XOMA, IRWD, VNDA, SGMO, LXRX, ACHV, and RGLS
Should you be buying Verastem stock or one of its competitors? The main competitors of Verastem include Emergent BioSolutions (EBS), Rigel Pharmaceuticals (RIGL), Codexis (CDXS), XOMA (XOMA), Ironwood Pharmaceuticals (IRWD), Vanda Pharmaceuticals (VNDA), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.
Verastem vs.
Verastem (NASDAQ:VSTM) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends, risk and community ranking.
Verastem has higher earnings, but lower revenue than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.
Verastem presently has a consensus target price of $13.63, suggesting a potential upside of 139.88%. Emergent BioSolutions has a consensus target price of $14.33, suggesting a potential upside of 85.16%. Given Verastem's higher probable upside, equities research analysts clearly believe Verastem is more favorable than Emergent BioSolutions.
Verastem has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.
Verastem received 187 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.77% of users gave Emergent BioSolutions an outperform vote while only 65.28% of users gave Verastem an outperform vote.
88.4% of Verastem shares are held by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are held by institutional investors. 2.2% of Verastem shares are held by company insiders. Comparatively, 1.2% of Emergent BioSolutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Verastem and Verastem both had 3 articles in the media. Emergent BioSolutions' average media sentiment score of 0.20 beat Verastem's score of 0.00 indicating that Emergent BioSolutions is being referred to more favorably in the news media.
Verastem has a net margin of 0.00% compared to Emergent BioSolutions' net margin of -18.55%. Emergent BioSolutions' return on equity of -9.91% beat Verastem's return on equity.
Summary
Verastem beats Emergent BioSolutions on 10 of the 16 factors compared between the two stocks.
Get Verastem News Delivered to You Automatically
Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verastem Competitors List
Related Companies and Tools
This page (NASDAQ:VSTM) was last updated on 2/21/2025 by MarketBeat.com Staff
